Baillie Gifford & Co. Sells 173,537 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Baillie Gifford & Co. lessened its position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 13.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,094,758 shares of the company's stock after selling 173,537 shares during the quarter. Baillie Gifford & Co. owned about 1.89% of Twist Bioscience worth $40,353,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. International Assets Investment Management LLC grew its stake in Twist Bioscience by 3,519.8% during the 4th quarter. International Assets Investment Management LLC now owns 4,018 shares of the company's stock worth $148,000 after buying an additional 3,907 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Twist Bioscience by 354.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,674 shares of the company's stock worth $246,000 after buying an additional 5,204 shares during the last quarter. Caprock Group LLC acquired a new stake in shares of Twist Bioscience in the 4th quarter valued at approximately $282,000. ARK Investment Management LLC lifted its holdings in shares of Twist Bioscience by 6.3% in the 4th quarter. ARK Investment Management LLC now owns 7,213,257 shares of the company's stock valued at $265,881,000 after buying an additional 427,274 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in shares of Twist Bioscience in the 4th quarter valued at approximately $619,000.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Barclays reduced their price target on Twist Bioscience from $45.00 to $40.00 and set an "overweight" rating for the company in a report on Wednesday. Scotiabank raised their price target on Twist Bioscience from $30.00 to $43.00 and gave the company a "sector outperform" rating in a report on Monday, February 5th. Finally, The Goldman Sachs Group raised Twist Bioscience from a "neutral" rating to a "buy" rating and raised their price target for the company from $25.00 to $45.00 in a report on Wednesday, January 17th.

Twist Bioscience Stock Performance

TWST stock traded down $1.87 during midday trading on Wednesday, hitting $31.86. 704,814 shares of the stock were exchanged, compared to its average volume of 923,018. The stock's 50-day moving average price is $36.42 and its 200-day moving average price is $29.60. The stock has a market cap of $1.84 billion, a price-to-earnings ratio of -8.83 and a beta of 1.62. Twist Bioscience Co. has a fifty-two week low of $11.46 and a fifty-two week high of $43.21.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings data on Friday, February 2nd. The company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.03. The firm had revenue of $71.50 million during the quarter, compared to analysts' expectations of $67.59 million. Twist Bioscience had a negative return on equity of 32.16% and a negative net margin of 78.44%. Twist Bioscience's revenue was up 31.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.74) earnings per share. Research analysts anticipate that Twist Bioscience Co. will post -3.17 EPS for the current year.

Insiders Place Their Bets

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,132 shares of the firm's stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $32.74, for a total transaction of $37,061.68. Following the completion of the transaction, the chief executive officer now owns 514,149 shares of the company's stock, valued at $16,833,238.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Emily M. Leproust sold 1,487 shares of Twist Bioscience stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $37.43, for a total value of $55,658.41. Following the completion of the sale, the chief executive officer now owns 516,409 shares of the company's stock, valued at $19,329,188.87. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Emily M. Leproust sold 1,132 shares of Twist Bioscience stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $32.74, for a total value of $37,061.68. Following the completion of the sale, the chief executive officer now directly owns 514,149 shares of the company's stock, valued at approximately $16,833,238.26. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 10,481 shares of company stock valued at $365,655. Corporate insiders own 3.92% of the company's stock.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.